Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.

Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP, Carrieri G.

Anticancer Res. 2009 Oct;29(10):4201-4.

2.

Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.

Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP, Carrieri G.

Urol Oncol. 2010 May-Jun;28(3):285-9. doi: 10.1016/j.urolonc.2008.08.003. Epub 2008 Oct 31.

PMID:
18976938
3.
4.

Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.

Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.

Anticancer Res. 2002 Nov-Dec;22(6B):3759-64.

PMID:
12552989
5.

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H.

Urol Oncol. 2013 Aug;31(6):849-56. doi: 10.1016/j.urolonc.2011.06.004. Epub 2011 Jul 22.

PMID:
21782482
6.

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.

Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y.

J Urol. 2007 Feb;177(2):481-7; discussion 487.

PMID:
17222615
7.

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy.

Peyromaure M, Weibing S, Sebe P, Verpillat P, Toublanc M, Dauge MC, Boccon-Gibod L, Ravery V.

Urology. 2002 Mar;59(3):409-13.

PMID:
11880082
8.

Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.

Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guillé F, Lobel B.

Eur Urol. 2002 Jun;41(6):635-41; discussion 642.

PMID:
12074781
9.

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.

J Clin Oncol. 2004 Mar 15;22(6):1014-24. Epub 2004 Feb 23.

PMID:
14981102
10.

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.

Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, Teh M.

Cancer. 2007 Mar 15;109(6):1097-105.

11.

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer.

Lebret T, Becette V, Barbagelatta M, Hervé JM, Gaudez F, Barré P, Lugagne PM, Botto H.

J Urol. 1998 Mar;159(3):788-91.

PMID:
9474149
13.

Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer.

Pollack A, Czerniak B, Zagars GK, Hu SX, Wu CS, Dinney CP, Chyle V, Benedict WF.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):687-95.

PMID:
9336151
14.

Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).

Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.

Eur Urol. 2004 Apr;45(4):475-82.

PMID:
15041112
15.

The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.

Yutkin V, Pode D, Pikarsky E, Mandelboim O.

J Urol. 2007 Dec;178(6):2660-4. Epub 2007 Oct 22.

PMID:
17945285
16.

Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.

Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M.

Eur Urol. 2009 Nov;56(5):829-36. doi: 10.1016/j.eururo.2008.09.062. Epub 2008 Oct 9.

PMID:
18926620
17.

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y.

Mod Pathol. 2007 Apr;20(4):445-59. Epub 2007 Mar 2.

18.

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ.

J Clin Oncol. 2004 Mar 15;22(6):1007-13. Epub 2004 Feb 23.

PMID:
14981105
19.
20.

Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder.

Sato M, Yanai H, Morito T, Oda W, Shin-no Y, Yamadori I, Tshushima T, Yoshino T.

Pathol Int. 2011 Aug;61(8):456-60. doi: 10.1111/j.1440-1827.2011.02694.x.

PMID:
21790859

Supplemental Content

Support Center